Navigation Links
Tengion to Present at UBS Global Life Sciences Conference
Date:9/14/2011

EAST NORRITON, Pa., Sept. 14, 2011 /PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced that Brian Davis, Vice President Finance and Chief Financial Officer of Tengion, will present at the upcoming UBS Global Life Sciences Conference on Monday, September 19, 2011, at 1:30 pm EDT.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investors section of the Company's website at www.tengion.com or by accessing http://cc.talkpoint.com/ubsx001/091911a_im/?entity=83_URMMK62.  Investors interested in listening to the live webcast should log on before the start time in order to download any software required.  A replay of the presentation will be available.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference
2. Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
3. Tengion Announces Leadership Transition
4. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
5. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
6. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
7. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
8. Tengion Announces Pricing of $31.4 Million Private Placement
9. Tengion Addresses Recent Trading Activity in its Common Stock
10. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
11. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... -- Personal Genome Diagnostics Inc. (PGDx) today announced that it ... Cancer Research (AACR) Annual Meeting 2017, being held April 1-5, ... also announced that five scientists associated with PGDx—two co-founders and ... AACR Team Science Award. ... Doug Ward , CEO of Personal ...
(Date:3/29/2017)... 29, 2017 QIAGEN N.V. (NASDAQ: QGEN ; ... U.S. launch of its ipsogen ® JAK2 RGQ PCR Kit ... Drug Administration as a qualitative in vitro diagnostic test for the detection of ... ... on QIAGEN,s Rotor-Gene ® Q MDx system, which is a member of ...
(Date:3/29/2017)... ... 29, 2017 , ... (March 29, 2017) — Nerium ... as an active member of the Mexican Direct Selling Association A.C. (AMVD ... in relationship marketing. This professional organization fosters loyal and fair competition among companies ...
(Date:3/29/2017)... CA (PRWEB) , ... March 29, 2017 , ... ... cutting edge instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy ... Today the company announced that its new round of awards are being ...
Breaking Biology Technology:
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
(Date:2/28/2017)... 2017 News solutions for biometrics, bag drop ... ... 14 to 16 March, Materna will present its complete end-to-end ... travel is a real benefit for passengers. To accelerate the ... passenger touch point solutions to take passengers through the complete ...
Breaking Biology News(10 mins):